The ABCs of Drug Testing

Slides:



Advertisements
Similar presentations
DC Responses Received WA OR ID MT WY CA NV UT CO AZ NM AK HI TX ND SD NE KS OK MN IA MO AR LA WI IL MI IN OH KY TN MS AL GA FL SC NC VA WV PA NY VT NH.
Advertisements

National Core Indicators Overview for the State of Washington Lisa A. Weber, Ph.D. Division of Developmental Disabilities.
OSBI Toxicology Lab Current Technologies for Blood Testing
1- Building up and maintaining a high-quality natural product library
Introduction to Analytical Chemistry Dr M. Abd-Elhakeem Faculty of Biotechnology General Chemistry Lecture 7.
1.2 Drawing Conclusions 2.3 Misuse & Abuse of Statistics.
NICS Index State Participation As of 12/31/2007 DC NE NY WI IN NH MD CA NV IL OR TN PA CT ID MT WY ND SD NM KS TX AR OK MN OH WV MSAL KY SC MO ME MA DE.
Toxicology. What is Toxicology? A diagnostic test that examines urine for the presence of prescription or illicit drugs.
R & D Assignment – Kinjal Ghia – DT204/ VANILLYLMANDELIC ACID [VMA]
In-vitro metabolite profiling of by LC-MS/MS Tejaswini Kailas Jadhav MS (Pharmaceutical Analysis) NIPER-A.
Lab # 6 ELISA Enzyme – Linked Immuno Sorbent Assay.
State and Local Health Department Governance Classification System
Medicaid Enrollment of New Eligibles in Expansion States, by Party Affiliation of Governor New Eligibles as a Percent of Total Medicaid Enrollment, FY.
Comparisons Of Different Modalities Michael Casarico LADC
Biologic Monitoring A. H. Mehrparvar, MD
Mass Spectrometry Vs. Immunoassay
Toxicology & Uncertainty in medical testing
Medicaid Enrollment of New Eligibles in Expansion States, by Party Affiliation of Governor New Eligibles as a Percent of Total Medicaid Enrollment, as.
WY WI WV WA VA VT UT TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
NGB / State WFF / Proposed Sourcing Solutions
Choosing the Best Urine Benzo Screen for Monitoring Adherence to Alprazolam or Clonazepam Maggie L Hopkins MD MBA1, Elisabeth Malmberg MS2, Bella Church.
Children's Eligibility for Medicaid/CHIP by Income, January 2013
Medicaid Income Eligibility Levels for Other Adults, January 2017
TOXICOLOGY.
Current Status of State Medicaid Expansion Decisions
States with Section 1115 ACA Expansion Waivers, December 2015
Expansion states with Republican governors outnumber expansion states with Democratic governors, May 2018 WY WI WV◊ WA VA^ VT UT TX TN SD SC RI PA OR OK.
Expansion states with Republican governors outnumber expansion states with Democratic governors, January WY WI WV◊ WA VA VT UT TX TN SD SC RI PA.
Forensic Toxicology.
Non-Citizen Population, by State, 2011
Private Sector Participation in Medicare: Exceeding Expectations
Share of Women Ages 18 – 64 Who Are Uninsured, by State,
Executive Activity on the Medicaid Expansion Decision, May 9, 2013
WY WI WV WA VA VT UT TX TN1 SD SC RI PA1 OR OK OH ND NC NY NM NJ NH2
WY WI WV WA VA VT UT TX TN1 SD SC RI PA OR OK OH1 ND NC NY NM NJ NH NV
Microbiome: Metabolomics
Mobility Update and Discussion as of March 25, 2008
Current Status of the Medicaid Expansion Decision, as of May 30, 2013
IAH CONVERSION: ELIGIBLE BENEFICIARIES BY STATE
We help food manufacturers make data-driven decisions.
Current Status of State Medicaid Expansion Decisions
State Health Insurance Marketplace Types, 2015
HHGM CASE WEIGHTS Early/Late Mix (Weighted Average)
PRACTICA & ONLINE ED AUTHORIZATION STATUS
Status of State Medicaid Expansion Decisions
Sampling Distribution of a Sample Mean
Medicaid Income Eligibility Levels for Parents, January 2017
Current Status of State Medicaid Expansion Decisions
S Co-Sponsors by State – May 23, 2014
Seventeen States Had Higher Uninsured Rates Than the National Average in 2013; Of Those, 11 Have Yet to Expand Eligibility for Medicaid AK NH WA VT ME.
Average annual growth rate
Sampling Distribution of a Sample Mean
Executive Activity on the Medicaid Expansion Decision, May 9, 2013
Current Status of State Medicaid Expansion Decisions
Volume 56, Issue 1, Pages (July 1999)
How State Policies Limiting Abortion Coverage Changed Over Time
United States: age distribution family households and family size
Status of State Medicaid Expansion Decisions
Chemical Laboratory Response Network
6-5 Collection and Preservation of Toxicological Evidence
Analytical Chemistry for the Biomedical Reader
Minimum Wage Discussion
Status of State Medicaid Expansion Decisions
Coming Soon to Your State!
Status of State Medicaid Expansion Decisions
Income Eligibility Levels for Children in Medicaid/CHIP, January 2017
WY WI WV WA VA VT UT TX TN SD SC RI PA OR OK OH ND NC NY NM NJ NH NV
Random Selection Students are selected by the drug testing company via computer program Student selected one month are still eligible for selection the.
Notes Page Title Here NCI Data on Outcomes:
The Role of the Toxicologist
Presentation transcript:

The ABCs of Drug Testing Travis Mays Section Head Analytical Chemistry (Drug Testing & Toxicology)

The Evolution of Drug Testing

Testing Methodologies Thin Layer Chromatography (TLC) Poor sensitivity An art to the science Masking Agents Time consuming Testing Methodologies

Enzyme-linked immunosorbent assay (ELISA) Improved sensitivity Cross-reactivity Expensive

Mass Spectrometry (LC/MS and GC/MS) Better sensitivity Accurate identification by mass Large drug libraries More automation

Livestock Show Drug Testing

Livestock Show Drug Testing ~60 shows/fairs in TX, including all Majors ~18 out of state shows (OK, NM, KS, MN, NE, LA, ND, MS, AZ, KY, TN, IN, GA, ID, MO, UT) >3,500 samples annually

Drug Classes Non-steroidal anti-inflammatory drugs (NSAIDs) Growth Promoting Drugs Steroids Stimulants Analgesics Sedatives/Tranquilizers Antipsychotics Muscle Relaxers Antidepressants Illicit Drugs (Drugs of Abuse) Anticonvulsants

Testing Overview

How Drug Testing is Conducted Screening Sample aliquot is extracted to isolate and concentrate target compound(s) The extract is screened by LC-MS Sample is either negative or suspicious If suspicious, sample undergoes confirmation testing

Screening

Screening

How Drug Testing is Conducted Confirmation A new aliquot is extracted targeting the suspicious drug(s) The extract is analyzed using LC-MS/MS If confirmed, the sample is reported as a positive finding

Confirmation

Screening LC/MS LC/MS/MS

Quantitative Testing We can provide drug concentrations for samples reported as positive Sample volume: Must have minimum amount required Used primarily for therapeutic drugs Interpretation What does the level indicate? Currently no published data to provide interpretation Future research projects pending

Sample Matrix Options Urine (20cc minimum) Serum/Plasma (5cc minimum) Feces – Poultry (*rabbits) (5g minimum) Retina Tissue – Beta-agonists (one intact, frozen eye) Tissue (20g minimum) Liver Muscle Kidney

Urine vs. Serum Urine Serum/Plasma What has the animal recently been exposed to (hours to days) Can detect metabolites More difficult to collect Serum/Plasma What is in the animal’s system at the time the sample was collected Lose ability to detect some metabolites Lose sensitivity for some drugs Easier to collect

Fee Structure Accession fee - $6 (per submission) Cost of testing (urine and serum/plasma) - $70 Quantitation – Additional $70 Retinas - $140 Tissue - $70 Turn-around Time – 5 to 10 business days May require an additional 1-3 days for quantitative testing

Submitting a Sample Order supplies in advance 120mL sterile urine cups @ $0.40/ea. Evidence tape @ $13.05/box

Chain of Custody

Split Sample Testing Split samples are collected and retained by the show (maintain chain of custody) If a sample is reported as Positive: The show will have the split sample tested at an independent lab OR The show will allow the owner to request a split sample test if not already performed by the show Can be expensive (~$500-$1,000)

Questions?? Travis Mays tmays@tvmdl.tamu.edu 979-845-3414